TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04266028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DM-101
Description: DM-101 administered by subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DM-101
Description: DM-101 administered by subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DM-101
Description: DM-101 administered by subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DM-101
Description: DM-101 administered by subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match DM-101
Description: Placebo to match DM-101 administered by SC injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match DM-101
Description: Placebo to match DM-101 administered by SC injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match DM-101
Description: Placebo to match DM-101 administered by SC injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match DM-101
Description: Placebo to match DM-101 administered by SC injection
Study: NCT00650546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 5 mcg twice a day titrated to 10 mcg twice a day
Study: NCT02870790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Description: one pill daily
Study: NCT01244152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive diabetes self-management education
Description: 18 group classes led by a dietitian and peer supporters, and weekly telephone calls by peer supporters. Intervention focus was on diet and physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced standard diabetes education
Description: 2 3-hour diabetes education classes taught by a health educator at a local clinic
Study: NCT03506971

Intervention type: OTHER
Group type: OTHER
Intervention: Psychologist's evaluation
Description: The research coordinator psychologist will evaluate: the development of the baby, the early interactions between the baby and his mother, attachment, maternal psychiatric symptoms, the experience of parenting and maternal sensitivity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric Nurse's interventions
Description: Pediatrics nurses perform preventive home visits that are based on : joint observation with the parents of the baby, play with the baby and his parents, interview with the parents on their parenthood~Rhythm of home visits:~* 1 every month from birth to 1 year~* 1 every 2 months from 1 year to 2 years~* 1 every 3 months from 2 years to 4 years

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint home visits
Description: Coordinating psychologist and the referent pediatric nurse will perform home visits. During this time, the psychologist evaluate : the development of the baby, the early interactions between the baby and his mother, attachment, maternal psychiatric symptoms, the experience of parenting and maternal sensitivity.~Rhythm of joint home visits:~* 1 at 4 months~* 1 at 24 months
Study: NCT03301051

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent VLP Vaccine
Description: Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of a Placebo
Study: NCT02042235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-implemented intervention
Description: In order to achieve the programme of parent-implemented language intervention, a detailed protocol for speech therapists recruited and trained for the present study has been established. The techniques and attitudes favouring use of oral language will be taught to the parents during 15 sessions with the parent(s) and child.
Study: NCT03969238

Intervention type: BEHAVIORAL
Intervention: Helpline
Description: This helpline will aim to provide patients with new diagnosis of pain who are prescribed opioids, access to education, support and free behavioral technique to help manage their pain such as mindfulness exercises. For those with opioid use disorder, the helpline will offer support in the form of education about the disorder, opioid withdrawal symptoms, risks of overdoses, and a variety of services such as help reach appropriate care with MAT licensed providers, information on FDA-approved MAT and naloxone, and, in some cases, behavioral intervention to keep patients engaged in treatment. The opioid helpline will provide a central resource for direct services and a portal for community services. It will also serve as a referral resource for health-care professionals.
Study: NCT01191489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Conditioned Oxygen Therapy in High Risk Patients
Description: OptiFlow system (R) with nasal cannula.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Conditioned Oxygen Therapy in High Risk Patients
Description: OptiFlow system (R) with nasal cannula.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive mechanical ventilation
Description: Bilevel pressure support through a facial mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Oxygen Therapy
Description: Conventional Oxygen Therapy with nasal cannula or Venturi facial mask.
Study: NCT03787667

Intervention type: DIAGNOSTIC_TEST
Intervention: CT or MRI based Radiomics
Description: Radiomic features were extracted from enhanced CT or MRI of colorectal cancer.
Study: NCT01813240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03219983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Patients will have an interscalene block under ultrasound guidance and receive .5% ropivacaine pre-operatively. Upon arrival to the Post-Operative Care Unit a continuous infusion of .5% ropivacaine will be started at 8ml/hr and increased by 2ml/hr every 15 minutes for pain score \> 4 with a maximum rate of 14ml/hr. Infusion will be delivered by ON-Q Select-a-Flow pump (volume 750ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal bupivacaine
Description: A total injection volume of 100ml will be comprised of 60ml 0.9% normal saline+ 20ml .5% bupivacaine + 20ml liposomal bupivacaine will be administered into the deep tissue of the operative are with an 18 or 20 gauge needle.
Study: NCT00497653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCI
Description: D-chiro-inositol 1200mg twicely daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, twice daily for 6 weeks
Study: NCT05226208

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual analogue scale (VAS)
Description: In the postpartum period all patients filled VAS and underwent interviews from the 1st to the 3rd day after delivery.

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual analogue scale (VAS)
Description: In the postpartum period all patients filled VAS and underwent interviews from the 1st to the 3rd day after delivery.

Intervention type: DIAGNOSTIC_TEST
Intervention: General anxiety scale (GAD-2) and survey
Description: In the postpartum period all patients filled survey with GAD-2 and underwent interviews from the 1st to the 3rd day after delivery.

Intervention type: DIAGNOSTIC_TEST
Intervention: General anxiety scale (GAD-2) and survey
Description: In the postpartum period all patients filled survey with GAD-2 and underwent interviews from the 1st to the 3rd day after delivery.
Study: NCT04418804

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chest ultrasound
Description: Each research volunteer will undergo a chest-directed ultrasound examination using a commercial device located in the Valley Hospital and approved for clinical use. After completing the above scan, the patient will undergo another ultrasound scan using a Vantage system device (by Verasonics), which is a research ultrasound device that will be provided on loan to the Haemek Hospital by the Weizmann Institute SAMPL Laboratory prior to the start of the trial. The scan will be made with a linear transducer sampled at a rate of about 8-12Mhz and / or with a curved transducer sampled at a rate of about 4-6Mhz.~The total estimated duration of the test is approximately 30 to 40 minutes per patient.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chest ultrasound
Description: Each research volunteer will undergo a chest-directed ultrasound examination using a commercial device located in the Valley Hospital and approved for clinical use. After completing the above scan, the patient will undergo another ultrasound scan using a Vantage system device (by Verasonics), which is a research ultrasound device that will be provided on loan to the Haemek Hospital by the Weizmann Institute SAMPL Laboratory prior to the start of the trial. The scan will be made with a linear transducer sampled at a rate of about 8-12Mhz and / or with a curved transducer sampled at a rate of about 4-6Mhz.~The total estimated duration of the test is approximately 30 to 40 minutes per patient.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chest ultrasound
Description: Each research volunteer will undergo a chest-directed ultrasound examination using a commercial device located in the Valley Hospital and approved for clinical use. After completing the above scan, the patient will undergo another ultrasound scan using a Vantage system device (by Verasonics), which is a research ultrasound device that will be provided on loan to the Haemek Hospital by the Weizmann Institute SAMPL Laboratory prior to the start of the trial. The scan will be made with a linear transducer sampled at a rate of about 8-12Mhz and / or with a curved transducer sampled at a rate of about 4-6Mhz.~The total estimated duration of the test is approximately 30 to 40 minutes per patient.
Study: NCT03627403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor will be administered orally at a dose of 80 mg once weekly until IWG-MR disease progression, intolerable toxicity, or no clinical benefit per treating physician's discretion whichever occurs first.~For patients enrolled after Protocol v7, Selinexor will be administered by oral route beginning at 40mg once weekly. Prior to protocol version 7, the starting dose of sSelinexor was 60 mg and 80 mg once weekly.
Study: NCT03843918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAE001
Description: LAE001 BID will be orally administered until the subjects develop disease progression, intolerable adverse events, or trial withdrawal decided by the investigator/subject. The LAE001 dose adopted for the phase II study will be based on the RP2D determined in the phase I study.
Study: NCT06559488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection [Avastin]
Description: Intravitreal bevacizumab (1.25 mg/0.05 mL) was injected at the completion of vitrectomy surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars Plana Vitrectomy
Description: routine procedure of pars plana vitrectomy in vitreous hemorrhage for proliferative diabetic retinopathy patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars Plana Vitrectomy
Description: routine procedure of pars plana vitrectomy in vitreous hemorrhage for proliferative diabetic retinopathy patients
Study: NCT04044729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: 500mg dose, suspended in medical grade olive oil and then mixed into chocolate pudding

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02450994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02568787

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rice bran arabinoxylan compound (RBAC)
Description: Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
Study: NCT01344460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadovist, BAY86-4875)
Description: a single bolus injection of approx. 0.1mmol/kg
Study: NCT00788671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03380143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Landscape Intervention
Description: Community and organization systems intervention targeting youth population physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practice
Description: Community development intervention
Study: NCT01001715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN475/SAR164877
Description: Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for REGN475/SAR164877)
Description: Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes
Study: NCT04449640

Intervention type: PROCEDURE
Intervention: Hysteroscopic septum resection.
Description: Resection of a uterine septum by hysteroscopic surgery.
Study: NCT01270373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FAC x 3 followed by Docetaxel x 3
Description: 5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles; followed by Docetaxel 100 mg/m2 every 21 days, for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel x 3 followed by FAC x 3
Description: Docetaxel 100 mg/m2 IV every 21 days, for 3 cycles; followed by 5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles
Study: NCT01249391

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splinting
Description: Gutter thermoplastic custom-made splint for nominated joint, to be worn at night-time for consecutive nights for 3 months
Study: NCT04312919

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Based Activity Intervention
Description: Providing youth and their families with access to the knowledge and resources to increase their physical activity will allow them to lead more healthy lifestyles will provide them with the foundation for a healthier life, and future ahead.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Activity Intervention
Description: Providing youth and their families with access to the knowledge and resources to increase their physical activity will allow them to lead more healthy lifestyles will provide them with the foundation for a healthier life, and future ahead.
Study: NCT03856671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin,metronidazole
Description: Orally intake neomycin 1g and metronidazole 0.2g four times before surgery
Study: NCT03543033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Description: These subjects will first receive a topical anesthesia to the skin and underlying tissue in a maximum amount of 5 ml of 1% Lidocaine. Following this application, an 18-20 gauge epidural needle will be used to inject a solution containing 80 mg Depo-Medrol in 1 ml of 1% PF Lidocaine and 5ml of sterile PF saline
Study: NCT00947765

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous blood injection
Description: Patients were infiltrated with injection of 2 ml autologous blood drawn from contra lateral upper limb vein mixed with 1 ml 0.5% bupivacaine, at the lateral epicondyle according to the standard technique.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local corticosteroid injection
Description: Patients were infiltrated with 2 milliliters of local corticosteroid (Methyl prednisolone acetate 80mg) mixed with 1 milliliters 0.5% Bupivacaine, at the lateral epicondyle according to the standard technique
Study: NCT03360526

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICSI
Description: Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. (Selecting an individual bound sperm with enhanced genetic and developmental integrity ensures that the sperm selected is the optimal sperm from the sample for oocyte injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TESA
Description: Patients will undergo TESA which is performed by sticking a needle in the testis and aspirating fluid and tissue with negative pressure then examine the sample for presence of motile~sperms followed by sample processing and oocyte injection.
Study: NCT02830230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab cefixime,Tab Azithromycin
Description: The women with clinical cervicitis will receive treatment for cervicitis.
Study: NCT01467570

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral rehydration solution Hipp ORS Apple 200
Description: Volume of the solution calculated by weight:~* fast oral rehydration in 3-4 hours by mouth~* ORS given for ongoing losses until diarrhea stops (maintenance phase)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ESPGHAN ORS
Description: Volume of the solution calculated by weight:~* fast oral rehydration in 3-4 hours by mouth~* ORS given for ongoing losses until diarrhea stops (maintenance phase)
Study: NCT03512626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OptiVis, Aaren Scientific
Description: All the surgeries were performed under topical anesthesia using a standard phacoemulsification procedure with Infiniti Vision System (all from Alcon Laboratories, Inc, Fort Worth, TX).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monofocal IOL
Description: All the surgeries were performed under topical anesthesia using a standard phacoemulsification procedure with Infiniti Vision System (all from Alcon Laboratories, Inc, Fort Worth, TX).
Study: NCT02713243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJN452
Description: Capsules containing LJN452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJN452
Description: Capsules containing LJN452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to LJN452
Description: Capsules containing placebo to LJN452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to LJN452
Description: Capsules containing placebo to LJN452
Study: NCT02617173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro 400 Matrix Therapy Products
Description: Positive electrical current with a low amplitude bellow sensation level situated on the scrotum.
Study: NCT05025982

Intervention type: PROCEDURE
Intervention: combination of lymphaticovenular anastomosis and liposuction
Description: Surgeries were carried out under local anesthesia and light sedation.LVA was performed adopting supramicrosurgical technique.Liposuction was performed following completion of the LVA
Study: NCT04009954

Intervention type: OTHER
Intervention: Fecal and blood samples collection for analysis
Description: Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs).

Intervention type: OTHER
Intervention: Fecal and blood samples collection for analysis
Description: Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs).
Study: NCT04090684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination Ciprofloxacin/Celecoxib
Description: Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day
Study: NCT01746563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection
Study: NCT04006639

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic Technique
Description: Patients undergoing tracheostomy procedure must be administered with analgesics, such Lidocaine 20% or Bupivacaine 0.5%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic Technique
Description: Patients undergoing tracheostomy procedure must be administered with analgesics, such Lidocaine 20% or Bupivacaine 0.5%
Study: NCT00080912

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Given in a single fraction or multiple fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Given in a single fraction or multiple fractions
Study: NCT01837901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcorneal electrostimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcorneal electrostimulation
Study: NCT01746563

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser therapy
Description: Laser therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: Laser therapy
Study: NCT04228289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU intranasal spray

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching intranasal spray
Study: NCT01837901

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcorneal electrostimulation
Study: NCT01401764

Intervention type: OTHER
Group type: OTHER
Intervention: Formulation buffers
Description: Platform II: Histidine, Polysorbate-80 PASS: Phosphate, Arginine, NaCl ARG 100: Phosphate, 100 mM Arginine
Study: NCT03077737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choose to Change
Description: Population-based letter outreach automated via the electronic health record system and text messaging targeted to low-income smokers. Paired with automated electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Enhanced usual care based on Ask, Advise and Refer in which an electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy) is made during a clinic visit.